Phaseline

Companies › Octapharma

Octapharma: clinical trials, targets and expected readouts

5 active drug programs in 8 registered trials: 6 Phase 3, 2 Phase 4; Immunology, Hematology, Neurology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Simoctocog Alfa
Coagulation factor VIII exogenous protein
F8Phase 4Severe Hemophilia A; Hemophilia AFeb 2027
Human plasma derived antithrombin (Atenativ)
Antithrombin (plasma-derived)
SERPINC1Phase 3Congenital Antithrombin Deficiency; Acquired Antithrombin DeficiencyDec 2026
OCTA-C1-INH
C1 esterase inhibitor (C1-INH) protein replacement
SERPING1Phase 3Acute Hereditary Angio EdemaDec 2026
Panzyga, 10%
Intravenous human immunoglobulin (IVIG)
–Phase 3Pediatric Chronic Inflammatory Demyelinating Polyneuropathy; HypogammaglobulinemiaDec 2028
Newnorm
Human normal immunoglobulin (20% subcutaneous formulation)
–Phase 3Primary Immune Deficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05935358Simoctocog AlfaPhase 4Severe Hemophilia AHematologyAug 2026
NCT04640142NewnormPhase 3Primary Immune DeficiencyImmunologySep 2026
NCT04918173Human plasma derived antithrombin (Atenativ)Phase 3Congenital Antithrombin DeficiencyHematologyDec 2026
NCT06361537OCTA-C1-INHPhase 3Acute Hereditary Angio EdemaImmunologyDec 2026
NCT05936580Simoctocog AlfaPhase 4Hemophilia AHematologyFeb 2027
NCT06096116Human plasma derived antithrombin (Atenativ)Phase 3Acquired Antithrombin DeficiencyHematologyMar 2028
NCT04929236Panzyga, 10%Phase 3Pediatric Chronic Inflammatory Demyelinating PolyneuropathyNeurologyDec 2028
NCT07220915Panzyga, 10%Phase 3HypogammaglobulinemiaInfectious diseaseDec 2029

Targets

F8 (1) SERPING1 (1) SERPINC1 (1)

Companies with the same targets

Pfizer Roche Swedish Orphan Biovitrum Sinocelltech ASC Therapeutics Bioverativ, a Sanofi company Biocad Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Swedish Orphan Biovitrum Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Longbio Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.